A generic medicine has to be a copy of something. A Reference Listed Drug is that something — the already-approved product a generic applicant compares its own product against.
The term gets used loosely in supplier offers and tender documents, often as shorthand for “the brand version”. That is close, but the regulatory meaning is narrower and it matters when money is at stake.
Get the definition wrong and you can buy comparator units a regulator will not accept, or believe a claim of equivalence that has never been tested.
Quick answer: A Reference Listed Drug (RLD) is an approved drug product that the FDA identifies as the basis for approving a generic. A generic applicant must show its product is pharmaceutically equivalent and bioequivalent to the RLD. RLDs are listed in the FDA Orange Book along with therapeutic equivalence codes, patents, and exclusivity.
Table of Contents
- What Is a Reference Listed Drug?
- The FDA Orange Book and How Products Are Listed
- Therapeutic Equivalence Codes Explained
- Reference Listed Drug vs Reference Standard
- RLD, Reference Standard, Generic and Authorised Generic Compared
- Pharmaceutical Equivalence, Bioequivalence and Therapeutic Equivalence
- How the RLD Is Used in a Bioequivalence Study
- The European Equivalent: Reference Medicinal Product
- Comparator Terminology Across US, EU and WHO
- Sourcing RLD Units in Practice
- Patents, Exclusivity and Paragraph Certifications
- Comparators in Emerging Market Registrations
- What Buyers Should Check When a Supplier Mentions an RLD
- Expert Tips
- Common Mistakes
- Frequently Asked Questions
What Is a Reference Listed Drug?
A Reference Listed Drug is an approved drug product that the US FDA identifies as the listed drug an applicant relies on when seeking approval of an abbreviated application. In practice it is almost always the original brand product, approved with its own safety and efficacy data.
The abbreviated pathway rests on one idea: if a copy delivers the same active substance into the bloodstream at the same rate and extent, the original product’s clinical data can be relied upon. The generic applicant does not repeat those trials.
That holds only if the copy is compared to a specific approved marketed product — not a specification, and not a competitor’s generic. The RLD also defines the labelling the generic must broadly match and the patents it must address.
The FDA Orange Book and How Products Are Listed
The Orange Book is the FDA publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, updated continuously and free to search.
It lists approved products by active ingredient, dosage form, strength, and applicant. It flags which are RLDs, assigns therapeutic equivalence codes, and carries patent and exclusivity information submitted by application holders.
It is not a quality certificate and not a supplier directory. Being listed means a product holds an approval, nothing about the batch in front of you. It also excludes biologics, which sit in a separate publication with its own interchangeability framework.
Therapeutic Equivalence Codes Explained
Therapeutic equivalence codes tell a pharmacist or purchaser whether one product can substitute for another with the expectation of the same clinical result. The first letter carries the meaning: A means therapeutically equivalent to its pharmaceutical equivalents, B means not, or not established.
| Code | Meaning in plain terms |
|---|---|
| AA | Conventional forms with no known bioequivalence problems |
| AB | Bioequivalence demonstrated with in vivo or in vitro data |
| AP | Injectable aqueous solutions considered equivalent |
| AT | Topical products considered equivalent |
| BX | Data insufficient to determine therapeutic equivalence |
| BC | Extended-release forms not shown to be equivalent |
| BP | Potential bioequivalence problems, not yet resolved |
A detail people miss: AB ratings can carry a number, such as AB1 or AB2. Products are substitutable only within the same numbered group, not across groups sharing an active ingredient.
A B rating does not mean the product is unsafe or poor quality. It means substitution without prescriber involvement is not supported by the available evidence.
Reference Listed Drug vs Reference Standard
This is the distinction competing articles usually blur, and it has consequences for anyone buying comparator units.
The Reference Listed Drug is the approved listed drug the application relies on. It sets the labelling basis and the patent and exclusivity position.
The Reference Standard is the specific product the FDA selects that an applicant must actually purchase and test against. Usually the same product is both, and the Orange Book flags them separately because they can diverge.
If the brand product is withdrawn for reasons unrelated to safety, it can remain the RLD while the FDA designates a marketed generic as the Reference Standard. The applicant still relies on the RLD for labelling and legal purposes but tests against the Reference Standard. Check both flags before buying a single unit.
RLD, Reference Standard, Generic and Authorised Generic Compared
| Aspect | Reference Listed Drug | Reference Standard | Generic | Authorised Generic |
|---|---|---|---|---|
| What it is | Listed drug relied on for a generic application | Product FDA selects for bioequivalence testing | Product approved via the abbreviated pathway | Brand product sold without the brand name |
| Approval basis | Full application, own clinical data | Whichever product FDA designates | Comparison to the RLD | The brand’s own application |
| Usually is | The innovator brand product | The same brand product | A copy by another company | The innovator’s product, relabelled |
| Role in a dossier | Labelling, patent, exclusivity basis | The comparator you buy and test | The applicant’s own product | Not a comparator; the RLD repackaged |
| Orange Book status | Flagged as RLD | Flagged as RS | Listed with a TE code | Not listed; separate FDA list |
| Practical relevance | What you must match | What you must purchase | What you sell | Same formulation, lower price |
An authorised generic causes real confusion in sourcing conversations. It is the brand product in generic clothing, made under the innovator’s application, so it is neither an independent generic nor a separate reference.
Pharmaceutical Equivalence, Bioequivalence and Therapeutic Equivalence
These three terms get used interchangeably in commercial emails. They are not the same, and the difference decides whether substitution is defensible.
Pharmaceutical equivalents contain the same active ingredient in the same amount, dosage form, and route. They may differ in excipients, colours, flavours, shape, and packaging.
Bioequivalence means no significant difference in the rate and extent to which the active moiety becomes available at the site of action, under the same conditions and dose.
Therapeutic equivalence combines both, plus adequate labelling and manufacture under good manufacturing practice. Only these earn an A code.
A pharmaceutical alternative is a weaker relationship — same active moiety, different salt, ester, or dosage form — and is not automatically substitutable.
How the RLD Is Used in a Bioequivalence Study
A standard oral bioequivalence study is a crossover design in healthy volunteers. Each subject receives the test and reference products in separate periods with a washout between, and the pharmacokinetic profile is calculated from blood samples.
The main measures are area under the concentration-time curve and peak concentration. In most regulated markets the criterion is that the 90% confidence interval of the test-to-reference ratio falls within 80 to 125 percent, with tighter limits for narrow therapeutic index drugs in some jurisdictions.
In vivo studies are not always required — some simple solutions, topicals, and biowaiver-eligible products rely on comparative dissolution data instead. Either way, the report records the comparator’s name, manufacturer, batch number, expiry date, and country of purchase.
The European Equivalent: Reference Medicinal Product
The EU concept is the reference medicinal product. A generic application must show the same qualitative and quantitative composition in active substances, the same pharmaceutical form, and demonstrated bioequivalence.
The reference must be, or have been, authorised in the European Economic Area, nationally or centrally. There is no Orange Book equivalent, so applicants identify the reference themselves and justify the choice with product information and proof of authorisation.
The EU also lets a comparator sourced in one member state support an application in another, provided the sponsor justifies that the products are the same. That flexibility does not exist in the same form in the US.
Protection is commonly described as eight years of data protection plus two years of market protection, with a possible additional year for a significant new indication. Treat that as a general rule, alongside the wider rules in how to import pharmaceuticals into Europe.
Comparator Terminology Across US, EU and WHO
| Concept | United States | European Union | WHO |
|---|---|---|---|
| The reference product | Reference Listed Drug (RLD) | Reference medicinal product | Comparator product |
| What you buy and test | Reference Standard (RS) | Sourced batch of the reference | The selected comparator |
| The copy | Generic drug | Generic medicinal product | Multisource product |
| Substitution concept | Therapeutic equivalence, coded A or B | Essential similarity and bioequivalence | Interchangeable multisource product |
| Where published | Orange Book | National and centralised registers | WHO guidance and comparator listings |
| Who picks it | FDA designates the RS | Applicant selects and justifies | WHO guidance or national authority |
Health Canada says “Canadian Reference Product” for the same idea, and several agencies simply say “innovator product”. The vocabulary changes; the science does not.
Sourcing RLD Units in Practice
Comparator sourcing sounds trivial and is often the slowest part of a generic programme. You need genuine market units, in the right strength, with enough shelf life to cover the study.
A crossover study can require hundreds of units, sometimes across batches. For hospital-only or restricted-distribution products, buying that quantity through normal channels can be impossible, which pushes sponsors towards specialist agencies licensed in the reference market.
Cold chain items add another layer, because a temperature excursion in transit can invalidate the units — this is where documented cold chain pharmaceutical logistics becomes the study itself. Shelf life is the quiet killer: units bought a year before dosing may not survive analysis timelines.
Patents, Exclusivity and Paragraph Certifications
The Orange Book also carries patent listings submitted by application holders and exclusivity periods granted by the FDA. Patents are private rights; exclusivity is a statutory period during which the FDA will not approve, or will not accept, certain applications.
Well-established examples include five years for a new chemical entity, three years tied to new clinical investigations, and seven years for orphan-designated indications, with pediatric studies adding a further period. Treat these as general rules and verify each case.
A generic applicant must address every patent listed for the RLD, using one of four certifications:
- Paragraph I — no patent information has been submitted
- Paragraph II — the listed patent has already expired
- Paragraph III — approval is sought only after the patent expires
- Paragraph IV — the patent is invalid, unenforceable, or will not be infringed
Paragraph IV triggers notice to the patent holder and often litigation, with a stay on approval if suit is filed within the statutory window. A separate route lets the applicant carve a patented indication out of the label instead.
For a buyer this is a timing question. A supplier’s US ship date can depend entirely on where its filing sits in this process.
Comparators in Emerging Market Registrations
Many regulators outside the US and EU do not maintain their own reference lists. Instead they require the comparator to come from a recognised reference country — typically the innovator product authorised in the US, a European member state, Japan, or Australia.
That creates a sourcing problem. A manufacturer registering in several markets may need data against comparators from different reference countries, or a justification that one dataset covers all of them.
Where the innovator product is not marketed locally, some authorities accept a comparator authorised elsewhere with documentation. Others insist on locally sourced units, which can stall a file for months.
Check this before designing the study. Requirements vary widely between pharmaceutical regulatory authorities, and comparator rules are one of the places they diverge most.
What Buyers Should Check When a Supplier Mentions an RLD
Supplier documents throw the term around freely. “RLD equivalent”, “same as RLD”, and “RLD-based formulation” are marketing phrases with no regulatory meaning on their own.
Ask which product, precisely: brand name, strength, dosage form, application holder, and market of approval. Then ask what evidence supports the comparison. A study report against a named comparator batch is evidence; a brochure statement is not. Questions worth asking:
- Which specific RLD or reference product was used, and where was it purchased?
- Is there a bioequivalence study report, and who conducted it?
- Is the product approved anywhere on that data, and with what therapeutic equivalence rating?
- If the claim concerns the API rather than the finished dosage form, is a Drug Master File available?
A product can be a perfectly good generic without formal RLD comparison, particularly where the market does not require one for that dosage form. That should be stated plainly rather than dressed up as equivalence.
Expert Tips
- Check the RS flag, not just the RLD flag, before buying comparator units. The Orange Book separates them for a reason, and the wrong purchase means a repeated study.
- Buy comparator stock with a long remaining shelf life. Finish dosing and analysis well before expiry, and keep the retention samples the protocol requires.
- Keep the full purchase trail from the first unit. Invoice, batch, expiry, country, and temperature records belong in the dossier; reconstructing them later rarely works.
- Confirm comparator origin rules in every target market before finalising the study design. One study can serve several markets, but only if origin was chosen with that in mind.
- Read the therapeutic equivalence code, including its number. AB1 and AB2 products share an active ingredient but are not substitutable for each other.
- Ask for the study report, not the summary, and apply the same evidence standard you would when verifying a pharmaceutical manufacturer.
Common Mistakes
- Assuming the RLD and Reference Standard are always the same product. Testing against the wrong one invalidates the bioequivalence study.
- Treating pharmaceutical equivalence as proof of interchangeability. Same ingredient and strength says nothing about absorption, so substitution claims fall apart under review.
- Reading a B code as a quality failure. It signals that substitution is not supported by data, and this misreading kills viable supply options.
- Sourcing the comparator from a convenient market rather than the required reference country. The regulator rejects the data and the study is repeated at full cost.
- Accepting “RLD equivalent” wording without a named product. You cannot answer a customer’s regulatory question and the tender is lost.
- Ignoring patent and exclusivity listings when planning launch timing. Commitments are made that the supplier legally cannot meet on that date.
Frequently Asked Questions
What does RLD stand for in pharma?
RLD stands for Reference Listed Drug. It is a US FDA term for an approved drug product a generic applicant relies on when seeking approval through the abbreviated pathway. Usually the RLD is the original brand product, approved on its own clinical trials. The generic applicant does not repeat those trials, but shows its product is pharmaceutically equivalent and bioequivalent to the RLD, which the Orange Book identifies.
What is the difference between RLD and Reference Standard?
The RLD is the approved listed drug a generic application relies on for labelling, patent, and exclusivity purposes. The Reference Standard is the product the FDA selects that the applicant must physically buy and test against in bioequivalence studies. Usually one product holds both roles. They separate when the brand is no longer marketed for reasons unrelated to safety, and the FDA designates an available generic as Reference Standard. Both are flagged in the Orange Book.
What is the FDA Orange Book?
The Orange Book is the FDA publication titled Approved Drug Products with Therapeutic Equivalence Evaluations. It lists approved products, identifies Reference Listed Drugs and Reference Standards, assigns therapeutic equivalence codes, and carries patent and exclusivity data from application holders. Pharmacists use it to judge substitutability; generic developers use it to find comparators and plan around patents. It is free to search and excludes biologics, which sit in a separate publication.
What does an AB rating mean?
An AB rating means the FDA considers a product therapeutically equivalent to its pharmaceutical equivalents, with bioequivalence demonstrated through acceptable data. AB-rated products can generally be substituted for one another with the expectation of the same clinical result. Where a rating carries a number, such as AB1 or AB2, substitution is supported only within that numbered group. Products in different groups were never shown equivalent to each other.
Is bioequivalence the same as therapeutic equivalence?
No. Bioequivalence means there is no significant difference in the rate and extent to which the active moiety reaches the site of action. Therapeutic equivalence is broader: products must be pharmaceutical equivalents, bioequivalent, adequately labelled, and made under good manufacturing practice. Bioequivalence is one component of therapeutic equivalence, not a synonym. Only products meeting every condition receive an A code and are treated as substitutable.
What is the EU equivalent of a Reference Listed Drug?
The EU uses the term reference medicinal product. A generic application must show the same qualitative and quantitative composition in active substances, the same pharmaceutical form, and demonstrated bioequivalence to that reference. The reference must be, or have been, authorised in the European Economic Area. Unlike the US there is no Orange Book equivalent, so the applicant identifies the reference product and justifies the choice.
How does a company source RLD units for a bioequivalence study?
Genuine market units are purchased in the reference country, through licensed distribution channels or specialist comparator sourcing agencies. A crossover study can need hundreds of units with enough shelf life to cover dosing and analysis. The purchase must be fully documented: invoice, country, batch number, expiry date, and temperature records. Restricted-distribution, hospital-only, and cold chain products are hardest to source, and comparator cost is often a major budget line.
What are Paragraph I to IV certifications?
They are the four ways a generic applicant addresses patents listed for the RLD. Paragraph I states no patent information has been submitted. Paragraph II states the patent has expired. Paragraph III seeks approval only after expiry. Paragraph IV asserts the patent is invalid, unenforceable, or not infringed. Paragraph IV requires notice to the patent holder and often leads to litigation, with approval stayed if suit is filed in time.
What is an authorised generic?
An authorised generic is the brand product marketed without its brand name, under the innovator’s own application. Formulation, manufacturing site, and specifications match the brand product. It is not an independent generic and not a separate reference product. The FDA publishes authorised generics in a separate list, since they are not distinct Orange Book entries. For buyers, an authorised generic competing on price is the RLD, not a copy of it.
Do emerging markets require a comparator from a reference country?
Many do. Where a regulator keeps no reference list of its own, it typically requires the innovator product authorised in a recognised reference country such as the US, an EU member state, Japan, or Australia. Some agencies publish an explicit list of acceptable origins; others require locally sourced units. Because requirements diverge, confirm comparator origin rules before designing the bioequivalence study, not after generating data.
Final Thoughts
The RLD is a narrow, defined thing. Treat it that way and the confusion in supplier conversations disappears, because the questions become specific: which product, which batch, which country, which study.
Suppliers who work in regulated markets answer those without hesitation. Those who cannot usually have a marketing claim rather than a dossier behind them.
Talk to Us About Comparator and Regulatory Requirements
AksharAvira Pharma supplies APIs, generics, and finished dosage forms across regulated and semi-regulated markets. To check what a target market expects for comparator data, or to review a supplier’s equivalence claims against our product range, speak with our pharmaceutical experts.